NF-κB and Inflammation

BioFiles 2007, 2.4, 14.

Inflammation and Cancer: the NF-κB Connection

Chronic inflammation is an underlying factor in the development and progression of many of the chronic diseases of aging, such as arthritis, atherosclerosis, diabetes, and cancer. Oxidative cellular stress induced by environmental factors, such as cigarette smoke, UV or ionizing radiation, bacterial or viral infection, or any number of oxidizing xenobiotic compounds, triggers a wide range of cellular responses, some of which are proinflammatory and proapoptotic, while others protect the cell against apoptosis and enhance cellular adhesion, cell proliferation, and angiogenesis. The inappropriate induction or constitutive activation of these protective responses in mutated or damaged cells appears to be a major factor in the transformation and proliferation of cancer cells.1–5

Two nuclear transcription factors that are involved in mediating the cellular responses to oxidative cell stress and proinflammatory stimuli are activator protein-1 (AP-1) and nuclear factor-κB (NF-κB). The role of these transcription factors on cancer initiation and progression has been studied in cell culture and in vivo models.5,6 The activation of two AP-1 components, c-Jun and c-Fos, by JNK and by ERK1/2 or p38 MAPK, respectively, is involved in the malignant transformation of cells stimulated by the tumor promotor phorbol 12-myristate 13-acetate (PMA). The proinflammatory and antiapoptotic response to tumor promotion is primarily mediated through activation of NF-κB by the IKK family of serine/threonine kinases. The following discussion will focus on the NF-κB pathway as a target for cancer chemotherapy and chemoprevention.

Figure 1. Many diverse stimuli utilize intracellular signaling pathways to activate NF-κB, a nuclear transcription factor that regulates proinflammatory and cell survival pathways.


NF-κB Transcription Factors

NF-κB refers to a family of transcription factors that has been highly conserved through evolution and is present in the cytoplasm of all cells. NF-κB has been called a “stress sensor” because its activity is induced by a wide variety of stimuli,7 including tumor necrosis factor (TNF-α), PMA and other tumor promoters, cigarette smoke extract (CSE), lipopolysaccharide (LPS), oxidants, and pathogenic bacteria. The NF-κB family comprises five members: p50 (NF-κB1), p52 (NF-κB2), RelA (p65), RelB, and c-Rel. p50 and p52 are cleaved from inactive precursor proteins, p105 and p100, respectively, prior to translocation to the nucleus. NF-κB family members are characterized by having:

  • a Rel homology domain that binds to DNA
  • a dimerization domain
  • the ability to bind to the intracellular inhibitor complex, IκB


The most widely studied NF-κB heterodimers are p50/p65 and p50/c-Rel (both associated with the classical or canonical pathway) and p52/RelB (alternative pathway). The classical pathway is activated by inflammatory cytokines, bacterial and viral infections, and oxidative stimuli and induces gene expression responsible for the antiapoptotic actions of NF-κB. The alternative pathway is primarily involved in B cell survival.2,7–9 The classical pathway is illustrated in Figure 1.

Cytoplasmic NF-κB is sequestered as an inactive complex with its regulatory subunit, IκB. The most abundant member of the IκB family of proteins is IκBα. Phosphorylation of two conserved serine residues in the N-terminal domain of the NF-κB/IκB complex induces the rapid dissociation and polyubiquitination of IκB followed by its degradation by the 26S proteasome. Activated NF-κB translocates to the nucleus where specific subunit lysines are acetylated by SRC-1 and p300 histone acetyltransferases. Acetylation promotes DNA binding and NF-κB-induced gene transcription.10 A list of more than 200 proteins that are regulated by NF-κB is given by Ahn and Aggarwal.7 Many of the genes regulated by NF-κB code for inflammatory cytokines and proteins that mediate cell survival, cellular adhesion, cell cycle activation, cell proliferation, angiogenesis, and oncogenesis. However, not all the actions of NF-κB promote cell survival. Activation of NF-κB also appears to be essential for p53-induced apoptosis in response to oxidative stress or to the anticancer agents, doxorubicin and etoposide.2,11

Activation of NF-κB via Phosphorylation

Phosphorylation of the NF-κB/IκB complex is catalyzed by IKK, a protein complex that contains two homologous kinase subunits (IKKα and IKKβ) and a regulatory subunit IKKγ/NEMO.17 Activation of the IKK complex can be initiated by any one of several intracellular phosphorylation pathways, including NF-κB-inducing kinase (TRAF/NIK),8,12,13 MEK1,11,14 ERK5,15 and PI3K/Akt.16 T cell, B cell and lysophosphatidic acid receptors activate a kinase cascade that results in the activation of the IKK complex by Bcl10, Malt1 and CARMA-1.9,17 Acetylation of serines and threonines in the activation loop of the IKKα and IKKβ subunits can prevent phosphorylation and activation of the IKK complex.18 In addition, regulation of the NF-κB/IκB complex can also occur independently of IKK activation or inhibition. Both the PI3K/Akt and JAK/STAT/Pim kinase pathways activate NF-κB by phosphorylating Cot, a serinethreonine kinase that can induce the proteasomal degradation of IκB.19 Upregulation or over-expression of mitogen activated protein kinase phosphatase-5 (MKP5) can decrease cytokine-induced phosphorylation of NF-κB/IκB and of p38 MAP kinase.20

There are two mechanisms by which the NF-κB-induced gene transcription is terminated. Genes coding for IκB complex proteins are upregulated by NF-κB. Newly formed IκBα subunits can enter the nucleus where they bind to and inactivate NF-κB, and the NF-κB/IκBα complex is exported back to the cellular cytoplasmic compartment.9 Alternatively, the translational action of DNAbound NF-κB can be terminated by deacetylation of the p65 subunit at Lys310 by the histone deacetylases SIRT1 or HDAC1.10,21 Inhibition of p300 histone acetyltransferase or the overexpression or activation of SIRT1 has been shown to inhibit NF-κB-mediated gene expression.10,22 Conversely, decreased histone deacetylase level or activity has been shown to increase the expression of inflammatory cytokines, presumably through enhancement of NF-κB-mediated gene transcription.23

NF-κB and its Relationship to Disease

Altered regulation of NF-κB activity is observed in many genetically- linked diseases and chronic diseases of aging, including cancer.7,9 NF-κB activation has been linked to inflammation-driven tumor promotion and progression. In addition, many solid and hematopoietic cancers express constitutively active NF-κB that contributes to the pathogenesis of the disease by inducing factors that promote proliferation, invasiveness, angiogenesis, and resistance to chemotherapeutic agents and radiation. Researchers have hypothesized that inhibition of NF-κB activation or transcriptional activity may delay cancer onset or may be used as an adjunct to more traditional chemotherapeutics. Many compounds, including many phytochemicals and micronutrients having putative chemopreventive properties, inhibit NF-κB activation or constitutive NF-κB activity in cellular or in vivo models of cancer.2,5,7,24 The anticancer activities of some of these phytochemicals are summarized in the table on page 16.

Many of the inducers of NF-κB also regulate other intracellular pathways that mediate cell cycle arrest or apoptosis. One hypothesis holds that inhibition of prosurvival pathways mediated via NF-κB allows expression of proapoptotic mechanisms that may also be mediated by the various cell signaling pathways. For example, TNF-α is an inflammatory cytokine that mediates a broad spectrum of biological actions via activation of the TNFR1 receptor and, depending on the cellular environment, can promote either cell survival or programmed cell death. On the one hand, TNF-α/TNFR1-induced activation of TRAF2 initiates kinase cascades that lead to phosphorylation and activation of AP-1 and NF-κB, thereby promoting gene expression, cell survival and proliferation. Conversely, through its interactions with TRADD or FADD, TNF-α/ TNFR1 initiates signaling pathways that activate caspase 8 and the proteolytic cascade that ends in apoptotic cell death. Furthermore, some of the genes induced by NF-κB activation, such as Gadd45β and XIAP, are inhibitors of prolonged JNK activation. JNK activation facilitates mitogen-induced and oxidative stress-induced apoptosis. Thus, in the presence of NF-κB inhibitors, TNFR1 activation would favor the proapoptotic, anticancer actions of TNF-α.2,13,25

It should be noted that many phosphorylation pathways, e.g., PI3K-Akt, JNK, and ERK, are involved in both prosurvival and proapoptotic cellular processes. Therefore, the physiological response to procarcinogenic and anticarcinogenic xenobiotics represents the sum of all the specific intracellular signaling pathways that are upregulated and down-regulated in response to these stimuli. While chemopreventive natural products may tip the balance toward cell death in some damaged or transformed cells, their actions may promote carcinogenesis or drug resistance in other cells or organisms.

Natural Product Inhibitors of NF-κB Activation

Compound Inducer Mechanism of NF-κB Inhibition Chemopreventive/ Chemotherapeutic Actions Ref. Cat. No. Pack Size
Betulinic acid TNF-α, IL-1β, PMA, H2O2, okadaic acid, cigarette smoke Inhibits activation of IKKα. Downregulates COX-2 and MMP-9. 26, 27 855057 100 mg
500 mg
Caffeic acid phenethyl ester (CAPE)   Suppresses p65 nuclear translocalization; inhibits MAPK. Decreases HIF-1α expression, induces HO-1 expression, reduces iNOS and MMP-9 expression 5, 27, 28 C8221 1 g
Curcumin TNF-α, PMA, H2O2 Inhibits phosphorylation of Akt and activation of IKKα; upregulates MKP5 expression, inhibits p38 activation. Also inhibits STAT3 and AP-1 activation and activates PPAR-γ; suppresses expression of c-Fos and c-Jun, inhibits COX-2 expression, antioxidant; blocks tumor initiation, promotion, invasion, angiogenesis, and metastasis. 5, 20, 29, 30, 31 C7727 ≥94% (curcuminoid content), ≥80% (Curcumin)
28260 Mixture of curcumin, desmethoxycurcumin and bisdesmethoxycurcumin, ≥95.0% (TLC)
500 mg
10 g
50 g
Embelin TNF-α, LPS, IL-1β, PMA, H2O2, okadaic acid, cigarette smoke Inhibits IKKα-induced phosphorylation of IκBα. Enhances apoptosis induced by cytokines and chemotherapeutic agents. 32 E1406 10 mg
50 mg
Epigallocatechin gallate PMA Inhibits IKK activation Also inhibits activation of AP-1, inhibits PI3K-Akt and ERK1/2 pathways, suppresses COX-2 induction, blocks H. pyloriinduced glycosylation of TLR-4. 5, 33 50299
≥97.0% (HPLC)
≥95%, from green tea
1 mg
50 mg
Evodiamine TNF-α, LPS, IL-1β, PMA, cigarette smoke Inhibits phosphorylation of Akt, association of Akt with IKKα, and activation of IKKα. Inhibits COX-2 induction, enhances apoptosis induced by cytokines and chemotherapeutic agents, inhibits TNF-induced invasive activity. Inhibits both constitutive and induced NF-κB; decreases HIF-1α expression. 28, 34,35 E3531 250 mg
Genistein 60Co Radiation, docetaxel, cisplatin   Potentiates radiation-induced apoptosis; upregulates p21WAF1/Cip1. 36 G6649 Synthetic, ≥98% (HPLC)
G6776 from Glycine max (soybean), ~98% (HPLC)
91955 BioChemika, ≥98.0% (HPLC)
5 mg
25 mg
100 mg
5 mg
10 mg
25 mg
100 mg
6-Gingerol TNF-α, IL-1β Upregulates MKP5 expression, inhibits p38 activation. Anti-inflammatory 20 G1046 n/a
Honokiol TNF-α, P. acnes Inhibits activation of IKKα and phosphorylation of Akt; operates downstream of MEKK-1. Downregulates genes involved in antiapoptosis, proliferation, invasion, and angiogenesis; downregulates COX-2. 37, 38, 39 H4914 10 mg
25 mg
Indole-3-carbinol TNF-α, LPS, IL-1β, PMA, H2O2, okadaic acid, cigarette smoke Inhibits activation of IKKα. Inhibits constitutive and induced NF-κB activation; binds to ERa, AhR, and AR and suppresses invasion and migration of human breast cancer cells. 40 I7256 1 g
5 g
25 g
Magnolol TNF-a, P. acnes Inhibits activation of IKKα and phosphorylation of Akt, operates downstream of MEKK-1. Downregulates COX-2 37,38 M3445 10 mg
Partenolide   Inhibits IKK   27 P0667 5 mg
25 mg
Piceatannol LPS Inhibits activation of IKKα and IKKβ, inhibits phosphorylation of Akt and Raf-1; inhibits Syk and p56lck activity. Inhibits iNOS and COX-2 induction and transcription of proinfl ammatory cytokine genes 41,42 P0453 5 mg
25 mg
Silibinin TNF-a Inhibits IKKα activity Inhibits constitutive and induced NF-κB, inhibits PI3K-Akt and ERK1/2 pathways, inhibits c-Jun and c-Fos activation; inhibits tumor invasion, angiogenesis. 33, 47, 48, 49, 50 S0417 1 g
10 g
Tetrandrine CD28, ConA, PHA, PMA + ionomycin Inhibits IKKα and β activity, inhibits activation of JNK, p38 MAPK, ERK. Antiinfl ammatory; also blocks AP-1 activation 51 T2695 1 g
Xanthohumol TNF-α   Antiangiogenic; suppresses iNOS expression. 52 X0379 5 mg

Abbreviations: PMA – phorbol myristate acetate; HO-1 – Heme oxygenase 1; MKP5 – mitogen activated protein kinase phosphatase-5; LPS – lipopolysaccharide; TNR-4 – Toll-like receptor-4; P. acnes – Propionibacterium acnes; ER-a – estogen receptor a; AhR – aryl hydrocarbon receptor; AR – androgen receptor; Con A – concanavalin A; PHA – Phasolus vulgaris lectin




  1. Kundu, J.K., and Surh, Y.J., Mutat. Res., 591, 123-146 (2005).
  2. Luo, J.L., et al., J. Clin. Invest., 115, 2625-2632 (2005).
  3. Nickoloff, B.J., et al., J. Invest. Dermatol., 124, x-xiv (2005).
  4. Schottenfeld, D., and Beebe-Dimmer, J., CA Cancer J. Clin., 56, 69-83 (2006).
  5. Surh, Y.J., et al., J. Nutr., 135, 2993S-3001S (2005).
  6. Hou, D.X., et al., J. Biomed. Biotechnol., 5, 321-325 (2004).
  7. Ahn, K.S., and Aggarwal, B.B., Ann. NY Acad. Sci., 1056, 218-233 (2005).
  8. Ramakrishnan, P., et al., Immunity, 21, 477-489 (2004).
  9. Yates, L. L., and Górecki, D.C., Acta Biochim. Pol., 53, 651-662 (2006).
  10. Yeung, F., et al., EMBO J., 23, 2369-2380 (2004).
  11. Armstrong, M.B., et al., Neoplasia, 8, 967-977 (2006).
  12. Hu, W.H., et al., J. Biol. Chem., 280, 29233-29241 (2005).
  13. van Horssen, R., et al., Oncologist, 11, 397-408 (2006).
  14. Zhi, L., et al., J. Leukoc. Biol., e-pub Feb. 8, 2007.
  15. Garaude, J., et al., J. Immunol., 177, 7607-7617 (2006).
  16. Agarwal, A., et al., Oncogene, 24, 1021-1031 (2005).
  17. Klemm, S., et al., Proc. Natl. Acad. Sci. USA, 104, 134-138 (2007).
  18. Mittal, R., et al., Proc. Natl. Acad. Sci. USA, 103, 18574-18579 (2006).
  19. Amaravadi, R., and Thompson, C.B., J. Clin. Invest., 115, 2618-2624 (2005).
  20. Nonn, L., et al., Carcinogensis, e-pub Dec. 6, 2006.
  21. Kim, Y.K., et al., Biochem. Biophys. Res. Commun., 347, 1088-1093 (2006).
  22. Kaeberlein, M., et al., J. Biol. Chem., 280, 17038-17045 (2005).
  23. Yang, S.R., et al., Am. J. Physiol. Lung Cell. Mol. Physiol., 291, L46-L57 (2006).
  24. Amiri, K.I., and Richmond, A., Cancer Metastasis Rev., 24, 301-313 (2005).
  25. Papa, S., et al., J. Cell Sci., 117, 5197-5208 (2004).
  26. Takada, Y., and Aggarwal, B.B., J. Immunol., 171, 3278-3286 (2003).
  27. Zhou, Y., et al., Endocr. Relat. Cancer, 12, S37-S46 (2005).
  28. Sun, H.L., et al., Oncogene, e-pub Jan. 8, 2007.
  29. Aggarwal, S., et al., Mol. Pharmacol., 69, 195-206 (2006).
  30. Shishodia, S., et al., Ann. NY Acad. Sci., 1056, 206-217 (2006).
  31. Thangapazham, R.L., et al., AAPS J., 8, E443-E449 (2006).
  32. Ahn, K.S., et al., Mol. Pharmacol., 71, 209-219 (2007).
  33. Singh, R.P., and Agarwal, R., Endocr. Relat. Cancer, 13, 751-778 (2006).
  34. Choi, Y.H., et al., Arch. Pharm. Res, 29, 293-297 (2006).
  35. Takada, Y., et al., J. Biol. Chem., 280, 17203-17212 (2005).
  36. Raffoul, J.J., et al., BMC Cancer, 6, 107 (2006).
  37. Ahn, K.S., et al., Mol. Cancer Res., 4, 621-633 (2006).
  38. Lee, J., et al., Planta Med., 71, 338-343 (2005).
  39. Tse, A.K., et al., Biochem. Pharmacol., 70, 1443-1457 (2005).
  40. Takada, Y., et al., Blood, 106, 641-649 (2005).
  41. Islam, S., et al., Microbiol. Immunol., 48, 729-736 (2004).
  42. Jin, C.Y., et al., Pharmacol. Res., 54, 461-467 (2006).
  43. Birrell, M.A., et al., FASEB J., 19, 840-841 (2005).
  44. Borra, M.T., et al., J. Biol. Chem., 280, 17187-17195 (2005).
  45. Lagouge, M., et al., Cell, 127, 1109-1122 (2006).
  46. Meng, Y., et al., World J. Gastroenterol., 11, 525-528 (2005).
  47. Chen, P.N., et al., Chem. Biol. Interact., 156, 141-150 (2005).
  48. Dhanalakshmi, S., et al., Oncogene, 21, 1759-1767 (2002).
  49. Singh, R.P., et al., Oncogene, 24, 1188-1202 (2005).
  50. Yoo, H.G., et al., Int. J. Mol. Med., 13, 81-86 (2004).
  51. Ho, L.J., et al., Brit. J. Pharmacol., 143, 919-927 (2004).
  52. Albini, A., et al., FASEB J., 20, 527-529 (2006).

back to top Back to Top

Related Links